Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.…
BioTech Breakthrough Acknowledges Champions Oncology Innovation with the "Contract Research and Development Innovation Award"
Champions Oncology (NASDAQ: CSBR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 214 employees.
The shares were at 4.340 USD on 20 November 2026, down 35.6% over 52 weeks. Its 52-week range is 4.340 USD to 8.310 USD, and it trades at the bottom of that range.
Its market capitalisation is 60.41M USD.
Champions Oncology reports return on equity of -29.8%, an operating margin of -1.5% and revenue up 8.8% year over year.
Its debt exceeds its cash by 6.61M USD, a debt-to-equity ratio of 1.15. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 15 December 2026.